HIPRA SARS-CoV-2 is a recombinant protein vaccine designed to optimize its safety and induce an immune response that neutralizes the COVID-19 virus and its variants.
HIPRA is committed to providing solutions that contribute to improving the global health, of both people and animals.
More than 50 years focused on research, production and commercialization of highly innovative vaccines.
HIPRA has a singular model that controls all phases of vaccine creation: research, production and marketing.
HIPRA has a strong international presence with a marketing and sales team distributed over 40 subsidiaries worldwide, which ensure that more than 100 countries can benefit from the products.
A team of more than 2,400 persons, multicultural and multidisciplinary, that under the same values, works to offer the best solutions.
Putting all the enthusiasm, knowledge and talent, HIPRA is committed to continue innovating in solutions that have a positive impact on global health.
Discover our latest news